beta
Trial Radar AI
Clinical Trial NCT07220382 (PRETOX) for Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View

Preoperative BOTOX® Injection for Large Ventral Hernia Repair (PRETOX) Phase 4 188 One-Time Treatment

Recruiting
Clinical Trial NCT07220382 (PRETOX) is designed to study Treatment for Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional. It is a Phase 4 interventional study that is recruiting, having started on 3 November 2025, with plans to enroll 188 participants. Led by The Cleveland Clinic, it is expected to complete by 15 December 2029. The latest data from ClinicalTrials.gov was last updated on 21 November 2025.
Brief Summary
This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection of a medicine commonly known as "BOTOX®" (onabotulinumtoxinA) into the side abdominal muscles 3-7 weeks before surgery helps surgeons close the abdominal wall fully at the end of the operation. Closing the muscle and tissue layers ("primary fascial closure") is ...Show More
Detailed Description
Background and Rationale:

Massive ventral hernias (pre-op axial width ≥15 cm and/or Tanaka volume ratio >25%) seldom achieve primary fascial closure (PFC) and are associated with higher respiratory morbidity, intensive care unit (ICU) utilization, post-operative pain, hospital length of stay (LOS), cost, and recurrence. Spasticity/fibrosis of the external oblique-internal oblique-transversus abdominis (EO/IO/TA) co...

Show More
Official Title

PREoperative Targeted OnabotulinumtoXina Injection for Abdominal Wall Reconstruction: A Randomized, Double-Blind, Placebo-Controlled Trial

Conditions
Hernia Abdominal WallBotox InjectionHernia Incisional VentralHernia Repair With Compartment SyndromeHernia SurgeryHerniaHernia Incisional
Other Study IDs
  • PRETOX
  • 25-824
NCT ID Number
Start Date (Actual)
2025-11-03
Last Update Posted
2025-11-21
Completion Date (Estimated)
2029-12-15
Enrollment (Estimated)
188
Study Type
Interventional
PHASE
Phase 4
Status
Recruiting
Keywords
BOTOX
Ventral Hernia
Abdominal Wall Reconstruction
OnabotulinumtoxinA
Preoperative BOTOX
Primary Fascial Closure
Fascial Bridging
Transversus Abdominis Release
Posterior Component Separation
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Triple
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalOnabotulinumtoxinA Group
These patients will receive image-guided botulinumtoxin injections as described 21-48 days prior to open ventral hernia repair.
OnabotulinumtoxinA Injection
A total of 300 units of onabotulinumtoxinA will be reconstituted 150 cc of injectable 0.9% NaCl (for a final concentration of 2 units / cc). Each side of the abdominal wall will receive a total 75 cc distributed across three injection sites (six injection sites total per patient). At each injection site, the muscle bodies of the transversus abdominis, internal oblique, and external oblique will receive an equivalent ...Show More
OnabotulinumtoxinA
300 units of onabotulinumtoxinA will be prepared and administered as described in: "Procedure/Surgery: OnabotulinumtoxinA Injections"
Open Ventral Hernia Repair
Open abdominal wall reconstruction will be conducted in our standard fashion for the repair of very large hernias. The surgery is the same for patients who are not in the study. Surgeons will be blinded to the study arm of participant patients.
Placebo ComparatorPlacebo Group
These patients will receive image-guided saline (placebo) injections as described 21-48 days prior to open ventral hernia repair.
Saline (placebo) Injection
150 cc of injectable 0.9% NaCl will be prepared. Each side of the abdominal wall will receive a total 75 cc distributed across three injection sites. At each injection site, the muscle bodies of the transversus abdominis, internal oblique, and external oblique will receive an equivalent volume of product under ultrasonic or radiographic visualization.
0.9 % Normal Saline
150cc of normal saline will be prepared and administered as described in: "Procedure/Surgery: Saline (placebo) Injection".
Open Ventral Hernia Repair
Open abdominal wall reconstruction will be conducted in our standard fashion for the repair of very large hernias. The surgery is the same for patients who are not in the study. Surgeons will be blinded to the study arm of participant patients.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Primary Fascial Closure (PFC) at conclusion of Hernia Surgery (Yes / No, determined by surgeon)
Primary fascial closure (PFC) is the successful closure of the hernia. It will be defined in a binary, categorical manner as: "Yes" (fascial closed) or "No" (fascia not closed and bridging mesh required). To be considered "Yes" for PFC, the midline anterior fascia must be completely re-approximated via absorbable running or figure-of-eight sutures. If any segment of the anterior fascia cannot be approximated and closed, the patient will require anterior bridging and this would be considered a failure of PFC. Surgeons will decide if the fascia can be closed or if it cannot be closed by their expertise and discretion. No prespecified criteria have been established which dictate operative decision-making. The study team will record an outcome of "Yes" for PFC if the fascia is successfully closed by the surgeon via an eligible technique as previously described.
This will be measured (recorded) on the day of the hernia repair surgery, which will be 21 to 48 days after receiving your BOTOX injection.
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
30-Day Surgical Site Occurrence (SSO) - Proportion of Participants (%)
SSOs will be abstracted from the clinical record in a prospective fashion. They are defined as wound-related problems at or near the incision within 30 days of surgery (e.g., infection, fluid or blood collections, wound separation, or skin edge death). These will be measured on an individual level basis, and will be captured via patient interview and chart review within the specified timeframe. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Surgical Site Infection (SSI) - Proportion of Participants (%)
Any incisional or organ/space infection within 30 days, identified by treating teams. These will be measured on an individual level basis, and will be captured via patient interview, clinician-report, and/or chart review within the specified timeframe. Defined via any antibiotic and/or antimicrobial treatment of an infection at the surgical site. Positive culture or proof of pathogen not needed. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day SSOPI (Surgical Site Occurrence Requiring Procedural Intervention) - Proportion of Participants (%)
These are SSO events (as described in 30-Day SSO outcome) that required a bedside/clinic or OR procedure (e.g., aspiration, drainage, debridement) within 30 days. Cumulative SSOPIs will be calculated for each group. Additionally, aggregate calculation for a study group: numerator = participants with ≥1 SSOPI; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Readmission - Proportion of Participants (%)
Any inpatient hospital readmission within 30 days of index surgery. "How measured": EHR review/REDCap; unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Reoperation - Proportion of Participants (%)
Any return to the operating room related to the index surgery within 30 days. "How measured": EHR/REDCap; unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Hospital Length of Stay - Days
Days from operation to hospital discharge. "How measured": EHR discharge date minus surgery date; unit = days.
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day ICU Admission - Proportion of Participants (%)
Any ICU care during the index stay or within 30 days (planned or unplanned). "How measured": EHR/REDCap; unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
Duration of Mechanical Ventilation (Index Hospitalization) - Hours
Total ventilator time during and after surgery until final extubation during the index stay. Will be sub-divided as during surgery and after surgery. "How measured": anesthesia/intensive care record; unit = hours (may also be displayed as days:hours)
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Myocardial Infarction (MI) - Proportion of Participants (%)
MI within 30 days per treating clinician diagnosis. "How measured": medical record review, patient interview, and/or clinical diagnosis. Unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Pneumonia - Proportion of Participants (%)
Clinically diagnosed pneumonia within 30 days. "How measured": patient interview, medical record review, or clinical diagnosis. Unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Renal Failure/Acute Kidney Injury (AKI) - Proportion of Participants (%)
Acute kidney injury/failure within 30 days. "How measured": clinician diagnosis, medical record review, and/or KDIGO Guidelines. Unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Post-operative Ileus - Proportion of Participants (%)
Ileus requiring clinical management within 30 days. Defined as placement of an nasogastric tube or clinical diagnosis by surgeon based on intolerance of oral intake or delayed return of bowel function. "How measured": medical record review or clinician diagnosis. Unit = participants (%).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Patient-Reported Outcomes Measurement Information System (PROMIS®) Pain Intensity Short Form 3a - T-Score (Raw Response score range: 0-10, Higher = Worse Pain)
Three-item pain intensity questionnaire. "How measured": PROMIS-3a administered at follow-up; raw sum (3-15) converted to T-score (mean 50, SD 10); higher scores = more pain (worse). Unit = T-score.
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Hernia-Related Quality-of-Life Survey (HerQLes) - Score (0-100; Higher = Better QoL)
12-item hernia-specific QoL instrument. "How measured": HerQLes administered at follow-up; score transformed 0-100, higher = better function/less disability. Unit = total score (0-100).
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
30-Day Complication Severity (Clavien-Dindo) - Distribution of Highest Grade (I-V)
Highest complication grade based on the Clavien-Dindo classification system per participant within 30 days. "How measured": graded in REDCap from clinical documentation; unit = participants in each grade (%). Minimum = I, maximum = V; higher grades = worse.
Approximately 30 to 45 days after hernia repair surgery, which would be approximately 2 to 3 months after injection procedure.
90-Day SSO - Proportion of Participants (%)
SSOs will be abstracted from the clinical record in a prospective fashion. They are defined as wound-related problems at or near the incision within 90 days of surgery (e.g., infection, fluid or blood collections, wound separation, or skin edge death). These will be measured on an individual level basis, and will be captured via patient interview and chart review within the specified timeframe. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day SSI - Proportion of Participants (%)
Any incisional or organ/space infection within 90 days, identified by treating teams. These will be measured on an individual level basis, and will be captured via patient interview, clinician-report, and/or chart review within the specified timeframe. Defined via any antibiotic and/or antimicrobial treatment of an infection at the surgical site. Positive culture or proof of pathogen not needed. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day SSOPI - Proportion of Participants (%)
These are SSO events (as described in 30-Day SSO outcome) that required a bedside/clinic or OR procedure (e.g., aspiration, drainage, debridement) within 90 days. Cumulative SSOPIs will be calculated for each group. Additionally, aggregate calculation for a study group: numerator = participants with ≥1 SSOPI; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day Complication Severity (Clavien-Dindo) - Distribution of Highest Grade (I-V)
Highest complication grade based on the Clavien-Dindo classification system per participant within 90 days. "How measured": graded in REDCap from clinical documentation; unit = participants in each grade (%). Minimum = I, maximum = V; higher grades = worse.
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day Comprehensive Complication Index (CCI) Score at 90 Days - Score
Comprehensive Complication Index® score, which is a weighted score based on the number of complications in each Clavien-Dindo group within 90 postoperative days. "How measured": the individuals CCI score at 90-days, as calculated via https://www.cci-calculator.com/.
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day Readmission - Proportion of Participants (%)
Any inpatient hospital readmission within 30 days of index surgery. "How measured": EHR review/REDCap; unit = participants (%).
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day Reoperation - Proportion of Participants (%)
Any return to the operating room related to the index surgery within 90 days. "How measured": patient interview, medical record review, surgeon report; unit = participants (%).
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day Patient-Reported Outcomes Measurement Information System (PROMIS®) Pain Intensity Short Form 3a - T-Score (Raw Response score range: 0-10, Higher = Worse Pain)
Three-item pain intensity questionnaire. "How measured": PROMIS-3a administered at follow-up; raw sum (3-15) converted to T-score (mean 50, SD 10); higher scores = more pain (worse). Unit = T-score.
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
90-Day Hernia-Related Quality-of-Life Survey (HerQLes) - Score (0-100; Higher = Better QoL)
12-item hernia-specific QoL instrument. "How measured": HerQLes administered at follow-up; score transformed 0-100, higher = better function/less disability. Unit = total score (0-100).
Approximately 3 months after hernia repair surgery, which would be about 4 to 5 months after injection procedure.
1-Year Surgical Site Occurrence (SSO) - Proportion of Participants (%)
SSOs will be abstracted from the clinical record in a prospective fashion. They are defined as wound-related problems at or near the incision within 1 year of surgery (e.g., infection, fluid or blood collections, wound separation, or skin edge death). These will be measured on an individual level basis, and will be captured via patient interview and chart review within the specified timeframe. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 1 year after hernia repair surgery
1-Year Surgical Site Infection (SSI) - Proportion of Participants (%)
Any incisional or organ/space infection within 1 year, identified by treating teams. These will be measured on an individual level basis, and will be captured via patient interview, clinician-report, and/or chart review within the specified timeframe. Defined via any antibiotic and/or antimicrobial treatment of an infection at the surgical site. Positive culture or proof of pathogen not needed. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 1 year after hernia repair surgery
1-Year SSOPI - Proportion of Participants (%)
These are SSO events (as described in 30-Day SSO outcome) that required a bedside/clinic or OR procedure (e.g., aspiration, drainage, debridement) within 1 year. Cumulative SSOPIs will be calculated for each group. Additionally, aggregate calculation for a study group: numerator = participants with ≥1 SSOPI; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 1 year after hernia repair surgery
1-Year Reoperation
Any return to the operating room related to the index surgery within 1 year. "How measured": patient interview, medical record review, surgeon report; unit = participants (%).
Approximately 1 year after hernia repair surgery
1-Year Reoperation for Hernia Recurrence
Any return to the operating room related repair of a hernia within 7 cm of the hernia repaired in the original surgery within 1 year. "How measured": patient interview, medical record review, surgeon report; unit = participants (%).
Approximately 1 year after hernia repair surgery
1-Year Hernia Recurrence (Clinical)
A recurrence after hernia repair is defined as a new hernia detected within 7cm of the original repair. The hernia must be determined via imaging (ultrasound, computed tomography scan, or magnetic resonance imaging scan) or the documented physical exam of a licensed practitioner. Determined as within 1 year of the hernia repair surgery.
Approximately 1 year after hernia repair surgery
1-Year Hernia Recurrence (Patient-Reported)
Patient self-reported concern for recurrence based on response to the the question, "Do you feel or see a bulge?" on the Ventral Hernia Recurrence Inventory (VHRI) questionnaire. Asked at 1 year.
Approximately 1 year after hernia repair surgery
1-Year Patient-Reported Outcomes Measurement Information System (PROMIS®) Pain Intensity Short Form 3a - T-Score (Raw Response score range: 0-10, Higher = Worse Pain)
Three-item pain intensity questionnaire. "How measured": PROMIS-3a administered at follow-up; raw sum (3-15) converted to T-score (mean 50, SD 10); higher scores = more pain (worse). Unit = T-score.
Approximately 1 year after hernia repair surgery
1-Year Hernia-Related Quality-of-Life Survey (HerQLes) - Score (0-100; Higher = Better QoL)
12-item hernia-specific QoL instrument. "How measured": HerQLes administered at follow-up; score transformed 0-100, higher = better function/less disability. Unit = total score (0-100).
Approximately 1 year after hernia repair surgery
2-Year Surgical Site Occurrence (SSO) - Proportion of Participants (%)
SSOs will be abstracted from the clinical record in a prospective fashion. They are defined as wound-related problems at or near the incision within 2 years of surgery (e.g., infection, fluid or blood collections, wound separation, or skin edge death). These will be measured on an individual level basis, and will be captured via patient interview and chart review within the specified timeframe. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 2 years after hernia repair surgery
2-Year Surgical Site Infection (SSI) - Proportion of Participants (%)
Any incisional or organ/space infection within 2 years, identified by treating teams. These will be measured on an individual level basis, and will be captured via patient interview, clinician-report, and/or chart review within the specified timeframe. Defined via any antibiotic and/or antimicrobial treatment of an infection at the surgical site. Positive culture or proof of pathogen not needed. Aggregate calculation for a population: numerator = participants with ≥1 SSO; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 2 years after hernia repair surgery
2-Year SSOPI - Proportion of Participants (%)
These are SSO events (as described in 30-Day SSO outcome) that required a bedside/clinic or OR procedure (e.g., aspiration, drainage, debridement) within 2 years. Cumulative SSOPIs will be calculated for each group. Additionally, aggregate calculation for a study group: numerator = participants with ≥1 SSOPI; denominator = all randomized participants who underwent surgery; unit = participants (%).
Approximately 2 years after hernia repair surgery
2-Year Reoperation
Any return to the operating room related to the index surgery within 2 years. "How measured": patient interview, medical record review, surgeon report; unit = participants (%).
Approximately 2 years after hernia repair surgery
2-Year Reoperation for Hernia Recurrence
Any return to the operating room related repair of a hernia within 7 cm of the hernia repaired in the original surgery within 2 years. "How measured": patient interview, medical record review, surgeon report; unit = participants (%).
Approximately 2 years after hernia repair surgery
2-Year Hernia Recurrence (Clinical)
A recurrence after hernia repair is defined as a new hernia detected within 7cm of the original repair. The hernia must be determined via imaging (ultrasound, computed tomography scan, or magnetic resonance imaging scan) or the documented physical exam of a licensed practitioner. Determined as within 2 years of the hernia repair surgery.
Approximately 2 years after hernia repair surgery
2-Year Hernia Recurrence (Patient-Reported)
Patient self-reported concern for recurrence based on response to the the question, "Do you feel or see a bulge?" on the Ventral Hernia Recurrence Inventory (VHRI) questionnaire. Asked at 2 years.
Approximately 2 years after hernia repair surgery
2-Year Patient-Reported Outcomes Measurement Information System (PROMIS®) Pain Intensity Short Form 3a - T-Score (Raw Response score range: 0-10, Higher = Worse Pain)
Three-item pain intensity questionnaire. "How measured": PROMIS-3a administered at follow-up; raw sum (3-15) converted to T-score (mean 50, SD 10); higher scores = more pain (worse). Unit = T-score.
Approximately 2 year after hernia repair surgery
2-Year Hernia-Related Quality-of-Life Survey (HerQLes) - Score (0-100; Higher = Better QoL)
12-item hernia-specific QoL instrument. "How measured": HerQLes administered at follow-up; score transformed 0-100, higher = better function/less disability. Unit = total score (0-100).
Approximately 2 year after hernia repair surgery
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Adult (greater than or equal to 18 years of age)
  • Candidate for elective open repair of ventral hernia
  • Preoperative imaging demonstrating either:
  • ventral hernia defect width of at lest 15 cm; AND/OR,
  • Tanaka volume ratio of at least 25%
  • Planned elective hernia repair in an open fashion via a midline laparotomy with posterior component separation and transversus abdominis release

  • Emergent cases
  • Pregnancy and/or breastfeeding at time of intramuscular injection
  • Inability to provide informed consent
  • Inability to receive either study intervention (i.e. allergy to local anesthetics utilized for intervention administration, allergy and/or contraindication to any botulinum toxin, inability to attend outpatient administration of study intervention, inability to conform to safety check schedule)
  • Known congenital or acquired neuromuscular disorder
  • Presence of stoma
  • Current infection at time of intramuscular injection
  • Flank hernias s defined by EHS L1-L4
  • BMI > 45 kg/m^2
  • Diaphragmatic hemiparesis or chronic obstructive pulmonary disease (COPD) with chronic oxygen dependence
The Cleveland Clinic logoThe Cleveland Clinic
Joseph and Florence Mandel Family Foundation logoJoseph and Florence Mandel Family Foundation
Study Responsible Party
Lucas Beffa, Principal Investigator, Assistant Professor of Surgery, The Cleveland Clinic
Study Central Contact
Contact: Lucas R Beffa, MD, 216-445-5975, [email protected]
Contact: William C Bennett, MD, MS, 216-445-9989, [email protected]
1 Study Locations in 1 Countries

Ohio

Cleveland Clinic Main Campus, Cleveland, Ohio, 44195, United States
Lucas R Beffa, MD, Contact, 216-445-5975, [email protected]
William C Bennett, MD, Contact, 216-313-8971, [email protected]
Lucas R Beffa, MD, Principal Investigator
Clayton C Petro, MD, Sub-Investigator
Benjamin T Miller, MD, Sub-Investigator
Ajita S Prabhu, MD, Sub-Investigator
David M Krpata, MD, Sub-Investigator
Luciano G Tastaldi, MD, Sub-Investigator
Recruiting